Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 monthsTop-line data expected year-end ...
Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15, 2026 (GLO ...
Seasonal allergies affect millions. Experts share strategies to prepare now and make spring allergy season more manageable.
Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 ...
From higher cancer risk to possible fetal abnormalities, Kolkata doctors weigh in on the pros and cons of pre-wedding ...
Long-term partnership secures high-quality active pharmaceutical ingredient supply for Lasix(R) ONYU and future pipeline products BURLINGTON, Mass. and VICENZA, Italy, April 15, 2026 /PRNewswire/ -- ...
Pembro, made by pharma giant MSD, is hailed as a drug that saves and prolongs lives but it comes at an exorbitant cost ...
Johnson & Johnson (JNJ) stock climbed after reporting Q1 2026 earnings that beat forecasts, posting $24.1B sales and raising ...
Two Alzheimer's drugs were hailed as treatments that would transform care. Why are barely any UK patients getting them?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results